Neon health banner with

Understanding Scleroderma: Autoimmune Activity, Connective Tissue Changes, Symptoms, and Treatment

KM

Introduction

Scleroderma is a rare disease affecting connective tissues, which provide structural support to the skin and internal organs. The condition can cause tissues to become abnormally hard or thick, potentially affecting the skin, blood vessels, and other parts of the body. Although its manifestations vary, scleroderma presents important medical challenges because of its potential to involve multiple tissues and organs.

According to NIH News in Health (2025), the exact cause of scleroderma remains unknown. However, researchers believe the condition is autoimmune in nature, meaning the body’s disease-fighting system mistakenly attacks its own cells and tissues. This abnormal response can trigger connective tissue cells to produce excessive amounts of collagen, a protein that contributes to tissue structure.

Excessive collagen accumulation can cause affected tissues to harden and tighten. Depending on the form of scleroderma, these changes may involve the skin and underlying structures or extend to blood vessels and major internal organs, including the heart, lungs, and kidneys. Individuals may also experience swelling or pain involving muscles and joints.

Understanding scleroderma requires recognizing its different forms, the biological processes associated with connective tissue changes, and the challenges involved in diagnosis and treatment. The National Institutes of Health emphasizes that medical care must account for individual symptoms and the specific tissues and organs affected.

Understanding Scleroderma and Connective Tissue

Connective tissue plays an essential structural role throughout the human body. According to NIH News in Health (2025), connective tissues support the skin and internal organs, helping maintain the structure of these important body components.

Scleroderma affects these tissues by causing abnormal hardening or thickening. These changes can occur in the skin, blood vessels, and other tissues, although the extent of involvement varies according to the form of the disease.

The condition is particularly important because connective tissue is not limited to the skin. When a disease affects connective tissues, its manifestations may extend to structures beneath the skin and potentially to internal organs.

NIH News in Health (2025) identifies two main types of scleroderma: localized and systemic. This distinction is fundamental to understanding why some individuals experience changes primarily involving their skin while others have disease affecting multiple body systems.

Recognizing the relationship between connective tissue and organ support provides a foundation for understanding the broader effects of scleroderma.

The Autoimmune Processes Associated With Scleroderma

The exact cause of scleroderma has not been established. However, NIH News in Health (2025) explains that researchers believe it is an autoimmune disease.

Autoimmune diseases involve abnormal activity of the body’s disease-fighting system. Rather than directing its activity exclusively against threats, the immune system attacks the body’s own cells and tissues.

In scleroderma, this abnormal activity is thought to produce tissue damage that stimulates connective tissue cells to manufacture excessive amounts of collagen.

The relationship between autoimmune activity and collagen production is central to the explanation of scleroderma presented by NIH.

Although the autoimmune explanation provides an important scientific understanding of the disease, the NIH article emphasizes that its exact cause remains unknown.

This distinction is important because identifying a suspected biological mechanism does not necessarily establish what initially causes a disease to develop.

Collagen Overproduction and Tissue Hardening

Collagen is a protein associated with the structure of connective tissues. Under the circumstances described in NIH News in Health (2025), connective tissue cells affected by scleroderma produce excessive quantities of collagen.

This abnormal production contributes to the accumulation of collagen within the skin and other tissues.

As collagen builds up, affected areas can become harder and tighter. These physical changes are among the defining characteristics of scleroderma.

The process illustrates how changes occurring at the cellular level can produce noticeable alterations in tissue structure.

Although the disease is frequently associated with skin hardening, collagen-related changes may also involve other tissues, depending on the form of scleroderma.

Understanding excessive collagen production is therefore essential to explaining why the disease can affect both external structures and internal body systems.

Localized Scleroderma and Skin Involvement

Localized scleroderma is one of the two main forms of the disease identified by NIH News in Health (2025).

This form usually affects the skin and the structures immediately beneath it.

The distinction is important because localized scleroderma generally involves a more limited distribution of affected tissues than systemic scleroderma.

Changes associated with the disease may include hardening or thickening of affected skin and underlying connective tissues.

The biological mechanism involving excessive collagen production helps explain how these structural alterations can develop.

Although localized scleroderma primarily involves the skin and underlying structures, medical evaluation remains important because symptoms can vary.

Distinguishing localized scleroderma from the systemic form helps healthcare professionals understand which tissues may be affected and determine an appropriate approach to care.

Systemic Scleroderma and Internal Organ Involvement

Systemic scleroderma differs from localized scleroderma because it affects multiple systems within the body.

According to NIH News in Health (2025), systemic scleroderma can involve the skin, underlying connective tissues, blood vessels, and major internal organs.

The NIH article specifically identifies the heart, lungs, and kidneys as organs that may be affected.

This broader pattern of involvement demonstrates why systemic scleroderma requires consideration of more than changes involving the skin.

The effects of the disease may extend to tissues and organs that perform essential functions throughout the body.

However, the specific organs involved can differ among individuals. The classification of systemic scleroderma does not mean that every affected person necessarily experiences involvement of all the organs identified.

Recognizing which tissues and organs are affected is therefore particularly important when determining medical treatment and identifying the healthcare professionals who should participate in a patient’s care.

Blood Vessel Changes and Tissue Abnormalities

Scleroderma can affect blood vessels in addition to the skin and other connective tissues.

NIH News in Health (2025) explains that the disease can cause blood vessels and other tissues to become hard or thick.

These changes reflect the broader nature of the disease and its potential to involve structures throughout the body.

Blood vessel involvement is particularly relevant when considering the systemic form of scleroderma, which can affect multiple body systems.

The NIH article does not identify specific vascular complications or establish that every individual with scleroderma develops blood vessel abnormalities.

Instead, it emphasizes that the tissues affected can vary.

Understanding that blood vessels may be involved helps explain why medical evaluation must consider the overall pattern of tissue changes rather than focusing exclusively on visible skin symptoms.

Muscle and Joint Pain Associated With Scleroderma

In addition to tissue hardening and thickening, scleroderma can produce symptoms involving muscles and joints.

According to NIH News in Health (2025), individuals with scleroderma may experience swelling or pain affecting these areas.

These symptoms demonstrate that the disease can involve discomfort as well as structural changes in connective tissues.

Muscle and joint symptoms are relevant to clinical assessment because they represent part of the range of manifestations healthcare professionals may need to evaluate.

However, the NIH article does not establish that all individuals with scleroderma experience these symptoms or that their severity is identical among patients.

The presence and nature of symptoms can differ, contributing to the challenges associated with identifying and managing the condition.

A comprehensive understanding of scleroderma therefore includes recognizing both abnormal tissue changes and the possibility of muscle or joint discomfort.

Differences Between Localized and Systemic Scleroderma

The distinction between localized and systemic scleroderma is central to understanding the disease.

Localized scleroderma usually affects the skin and the structures underneath it. Systemic scleroderma involves a broader range of body systems, potentially including blood vessels and major internal organs.

Both forms are associated with abnormalities involving connective tissues, but the extent of affected structures differs.

This difference has important implications for medical evaluation because the symptoms and tissues involved help determine the appropriate approach to treatment.

NIH News in Health (2025) emphasizes that treatment depends on the individual’s symptoms and the organs or tissues affected.

Therefore, recognizing the form of scleroderma is part of understanding the nature of the disease in a particular patient.

The distinction also demonstrates why scleroderma cannot be adequately characterized as a condition involving only the skin, despite the importance of skin changes in its presentation.

Challenges in Diagnosing Scleroderma

Diagnosing scleroderma can be difficult because its symptoms vary.

NIH News in Health (2025) specifically identifies this variation as a challenge for healthcare professionals attempting to recognize the disease.

Some individuals may experience manifestations primarily involving the skin and underlying structures, while others may have broader involvement of tissues and internal organs.

Additional symptoms, such as muscle or joint pain and swelling, may also be present.

The range of possible manifestations means that the disease does not necessarily appear in the same way in every affected individual.

Understanding the difference between localized and systemic scleroderma is therefore relevant to the diagnostic process.

The NIH article does not provide specific diagnostic tests or procedures. Instead, it emphasizes the complexity created by differences in symptoms and the tissues involved.

This highlights the importance of appropriate professional evaluation when scleroderma is suspected.

Treatment Approaches and Individual Patient Needs

Treatment for scleroderma depends on the symptoms a person experiences and the tissues and organs affected by the disease.

According to NIH News in Health (2025), treatment decisions must reflect these individual differences.

This approach is particularly relevant because localized and systemic scleroderma can involve different patterns of tissue involvement.

For a person whose disease primarily affects the skin, the medical considerations may differ from those of an individual with involvement of major internal organs.

Similarly, the presence of muscle or joint symptoms may be relevant to understanding the patient’s overall condition.

The NIH article does not identify a specific medication or treatment protocol for scleroderma. Rather, it emphasizes that treatment must be determined according to the characteristics of each patient’s disease.

This individualized approach recognizes that the condition can vary considerably in its manifestations and the body systems affected.

The Role of Rheumatologists in Scleroderma Care

People with scleroderma often receive treatment from a rheumatologist.

NIH News in Health (2025) identifies rheumatologists as healthcare professionals commonly involved in managing the disease.

Their involvement is relevant because scleroderma is associated with connective tissue abnormalities, suspected autoimmune activity, and symptoms that may affect muscles, joints, and other body structures.

However, treatment may require participation from additional medical specialists.

The NIH article explains that different types of doctors may become involved depending on which organs are affected.

This consideration is especially important for systemic scleroderma, which can involve major organs such as the heart, lungs, and kidneys.

The involvement of multiple healthcare professionals reflects the potentially broad distribution of the disease throughout the body.

Coordinating medical care according to the affected tissues and organs is therefore an important consideration in understanding how scleroderma is managed.

Understanding the Broader Medical Significance of Scleroderma

Although scleroderma is classified as a rare disease, its potential effects on connective tissue and internal organs make it an important medical condition.

The disease demonstrates how abnormalities involving the body’s immune response and connective tissue production may be associated with changes affecting multiple structures.

NIH News in Health (2025) describes a process in which excessive collagen production contributes to tissue hardening and tightening.

The resulting manifestations can differ depending on whether the disease is localized or systemic.

This variation creates challenges for diagnosis and requires treatment approaches based on individual symptoms and the distribution of affected tissues.

The possibility of internal organ involvement further emphasizes why systemic scleroderma must be understood as more than a disease of the skin.

Greater awareness of these distinctions can help individuals better understand the condition and the reasons that different medical specialists may participate in its evaluation and treatment.

Conclusion

Scleroderma is a rare connective tissue disease that can cause the skin, blood vessels, and other tissues to become abnormally hard or thick. The condition may also produce swelling or pain involving muscles and joints, with manifestations that vary among affected individuals.

According to NIH News in Health (2025), the exact cause of scleroderma remains unknown, although researchers believe it involves autoimmune activity. This process can stimulate connective tissue cells to produce excessive collagen, contributing to the characteristic hardening and tightening of affected tissues.

The two main forms of scleroderma differ in their distribution throughout the body. Localized scleroderma usually affects the skin and underlying structures, while systemic scleroderma can involve multiple body systems, including blood vessels and major organs such as the heart, lungs, and kidneys.

The diversity of symptoms and patterns of tissue involvement creates important challenges for diagnosis and treatment. Consequently, medical care must account for the individual’s particular symptoms and the organs or tissues affected.

Rheumatologists frequently participate in the treatment of scleroderma, while additional medical specialists may be involved when the disease affects specific internal organs.

Ultimately, understanding scleroderma requires recognizing the relationship between suspected autoimmune activity, excessive collagen production, connective tissue abnormalities, and the potential involvement of multiple body systems. Awareness of these characteristics provides a foundation for understanding the importance of individualized medical evaluation and treatment.

References

NIH News in Health. (2025, June). What is scleroderma? National Institutes of Health.

Publisher website: NIH News in Health

Original article: What Is Scleroderma?

Kickoff Ministry: Instagram | Facebook

More From $100